PharmaTher (PHRRF) News Today $0.17 +0.02 (+10.85%) (As of 11/22/2024 04:22 PM ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period PharmaTher Holdings Ltd.: PharmaTher Announces Update on FDA New Drug Application for KetamineNovember 19, 2024 | finanznachrichten.dePharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug ApplicationNovember 13, 2024 | globenewswire.comPharmaTher receives CRL from FDA for ketamine ANDAOctober 24, 2024 | markets.businessinsider.comPharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug ApplicationOctober 24, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In October 2024September 30, 2024 | markets.businessinsider.comPharmaTher Announces Update on FDA New Drug Application for KetamineSeptember 4, 2024 | globenewswire.comPharmaDrug’s Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious DiseasesAugust 28, 2024 | msn.comPharmaDrug’s Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) ProteinsAugust 21, 2024 | msn.comPharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) ProteinsAugust 21, 2024 | globenewswire.comPharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated CepharanthineAugust 20, 2024 | msn.comPharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)August 20, 2024 | markets.businessinsider.comPharmaTher's Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)August 19, 2024 | globenewswire.comPharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 17, 2024 | stockhouse.comPharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 15, 2024 | finance.yahoo.comPharmaTher Holdings Ltd.: PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 11, 2024 | finanznachrichten.dePharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 10, 2024 | globenewswire.comPharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineMay 1, 2024 | finance.yahoo.comPharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineMay 1, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 18, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 16, 2024 | globenewswire.comPharmaTher Holdings Stock (OTC:PHRRF), Short Interest ReportFebruary 23, 2024 | benzinga.comPharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | finance.yahoo.comPharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | globenewswire.comPharmaTher Holdings Ltd.: PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finanznachrichten.dePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finance.yahoo.comPharmaTher Holdings Stock (OTC:PHRRF) Dividends: History, Yield and DatesJanuary 16, 2024 | benzinga.comPharmaTher Holdings Ltd.: PharmaTher Provides Update for Expected FDA Approval of KetamineJanuary 10, 2024 | finanznachrichten.dePharmaTher expects FDA to decide on ketamine approval by April 29January 10, 2024 | msn.comPharmaTher Provides Update for Expected FDA Approval of KetamineJanuary 10, 2024 | finance.yahoo.comPHRRF PharmaTher Holdings Ltd.December 23, 2023 | seekingalpha.comPharmaTher Holdings Ltd PHRRFNovember 11, 2023 | morningstar.comPharmather Holdings Ltd (PHRM)November 11, 2023 | investing.comPharmaTher Holdings Ltd.: PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)September 27, 2023 | finanznachrichten.dePharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)September 27, 2023 | finance.yahoo.comWith ecstasy a potential PTSD therapy, psychedelic treatments could take offSeptember 17, 2023 | msn.comPharmaTher Aims To Mitigate Ketamine Shortage With New FDA ApplicationSeptember 6, 2023 | benzinga.comPharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDASeptember 6, 2023 | finance.yahoo.comPharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical StageJuly 18, 2023 | benzinga.comPharmaDrug Inc.: PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.July 18, 2023 | finanznachrichten.dePharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.July 18, 2023 | finance.yahoo.comPharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo TherapeuticsJuly 18, 2023 | finance.yahoo.comKetamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip AssetsJune 27, 2023 | benzinga.comPharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDAJune 27, 2023 | finance.yahoo.comPharmaTher's Novel Ketamine Heads For The US Market With New Collaboration AgreementJune 21, 2023 | msn.comPharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.June 20, 2023 | finance.yahoo.comPharmaTher Holdings Ltd.: PharmaTher Holdings Provides Corporate UpdateJune 12, 2023 | finanznachrichten.dePharmaTher Holdings Provides Corporate UpdateJune 12, 2023 | benzinga.comParkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast TrackMay 3, 2023 | msn.comPharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s DiseaseMay 2, 2023 | finance.yahoo.comPsyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & MoreApril 5, 2023 | msn.com Get PharmaTher News Delivered to You Automatically Sign up to receive the latest news and ratings for PHRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Top secret Trump trades? (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.” Go here to see how you can start accessing these opportunities today PHRRF Media Mentions By Week PHRRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHRRF News Sentiment▼0.000.50▲Average Medical News Sentiment PHRRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHRRF Articles This Week▼10▲PHRRF Articles Average Week Get PharmaTher News Delivered to You Automatically Sign up to receive the latest news and ratings for PHRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:PHRRF) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaTher Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaTher With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
